The combined power of Caris' DNA, RNA, and
imaging data with COTA's curated clinical data strengthens the
offering to drive next-gen therapeutic development and advance
patient care
IRVING,
Texas and NEW YORK,
April 30,
2024 /PRNewswire/ -- Caris Life
Sciences®(Caris), the leading next-generation AI TechBio
company and precision medicine pioneer that is actively developing
and delivering innovative solutions to revolutionize healthcare and
improve the human condition using molecular science and AI,
and COTA, Inc. (COTA), an oncology real-world data (RWD) and
analytics company used by the world's leading pharmaceutical
companies, today announced a collaboration to expand their
multi-modal data offerings to support and accelerate
biopharmaceutical drug development and patient care.
Caris' partnership with COTA enables
biopharma to leverage a more complete dataset to power research and
AI approaches
The combination of the breadth and depth of Caris' genomic,
transcriptomic, proteomic and imaging data and COTA's high-quality
curated clinical data that captures the treatment journeys and
outcomes of cancer patients will result in a broad real-world,
multi-modal data offering, at scale, to power the next wave of
cancer therapeutics.
"Caris' partnership with COTA will enable biopharma to leverage
a more complete dataset to power research and AI approaches for
therapeutic development. This breadth of data allows the
flexibility to build specific cohorts for understanding mechanisms
of resistance, determinants of response and relevant biomarkers to
improve success of their clinical trials," said Brian Lamon, PhD, Chief Business Officer at
Caris.
As the pioneer in precision medicine and molecular profiling,
Caris has created a molecular-rich, multi-modal database generated
from nearly 10 million tests that contains more than 60 petabytes
of oncology-specific genomic, transcriptomic, proteomic and imaging
data. Caris was the first in the molecular diagnostic industry to
provide Whole Exome Sequencing (WES) DNA coverage and Whole
Transcriptome Sequencing (WTS) RNA coverage for every viable
sample.
"By combining COTA's high-quality, curated data sourced from
electronic health records with Caris' molecular data, life sciences
researchers will be able to capture previously unseen insights to
optimize cancer treatments that can improve a patient's prognosis
and quality of life," said C.K. Wang, MD, Chief Medical
Officer at COTA.
COTA's data includes more than two million cancer patients who
have received treatment across 200 sites of care in both academic
medical centers and community practices in rural and urban
settings, providing a powerful representative picture of cancer
care across the U.S. COTA synthesizes those records into data that
life sciences companies use to develop better, more personalized
cancer treatments.
About Caris Life Sciences
Caris
Life Sciences® (Caris) is the leading
next-generation AI TechBio company and precision
medicine pioneer that is actively developing and delivering
innovative solutions to revolutionize healthcare and improve the
human condition using molecular science and AI. Through
comprehensive molecular profiling (Whole Exome and
Whole Transcriptome Sequencing) and the application of
advanced AI and machine learning algorithms, Caris has
created the large-scale, multi-modal database and computing
capability needed to analyze and unravel the molecular complexity
of disease. This convergence of sequencing power, big data and AI
technologies provides an unmatched platform to deliver the next
generation of precision medicine tools for early detection,
diagnosis, monitoring, therapy selection and drug
development.
Headquartered in Irving, Texas,
Caris has offices in Phoenix, New
York, Cambridge (MA),
Tokyo, Japan and Basel, Switzerland. Caris or its distributor
partners provide services in the U.S., Europe, Asia
and other international markets. To learn more, please visit
CarisLifeSciences.com.
About COTA, INC.
Founded by oncologists, COTA is
committed to creating a precise, patient-first approach to cancer
care through the use of real-world data. The company leverages
technology-supported data abstraction methods to make sense of
complex, fragmented patient data from the real world. Offering the
highest quality oncology real-world data from leading academic and
community-based cancer centers and an advanced analytics platform,
COTA partners with leading life sciences companies, providers, and
payers to ensure that everyone touched by cancer has a clear path
to the right care. To learn more about COTA and how to fast-track
improvements in cancer care and treatment with comprehensive and
diverse real-world data and analytics, visit
cotahealthcare.com.
Caris Life Sciences Media Contact:
Lisa Burgner
Corpcomm@CarisLS.com
214.294.5606
COTA, Inc. Media Contact:
Jaimee Ryan
SVP Marketing
COTA Healthcare
jaimeeryan@cotahealthcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-and-cota-inc-announce-collaboration-to-expand-collective-multi-modal-data-offering-302130910.html
SOURCE Caris Life Sciences